Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
Study Details
Study Description
Brief Summary
RATIONALE: Drugs used in chemotherapy such as epirubicin and docetaxel use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as pegfilgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy.
PURPOSE: Phase I/II trial to study the effectiveness of combining epirubicin and docetaxel with pegfilgrastim in treating women who have locally advanced or inflammatory breast cancer.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
OBJECTIVES:
-
Determine the maximum tolerated dose and recommended phase II dose of docetaxel and epirubicin when given with pegfilgrastim in women with locally advanced or inflammatory breast cancer. (Phase I, group 1 closed to accrual as of 9/13/04 and Phase II, group 1 closed to accrual as of 5/10/06)
-
Determine the toxicity of this regimen in these patients.
-
Determine the clinical and pathological response rate and duration of response in patients treated with this regimen.
-
Determine drug sensitivity and resistance in patients treated with this regimen.
-
Determine prognostic and predictive markers in patients treated with this regimen.
OUTLINE: This is a nonrandomized, multicenter, dose-escalation study of docetaxel and epirubicin.
- Phase I:
Group 1 (21-day regimen) (closed to accrual as of 09/13/04): Patients receive epirubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with objective response after 6 courses may receive additional therapy at the discretion of the physician.
Group 2 (14-day regimen): Patients receive epirubicin IV over 15 minutes and docetaxel IV over 60 minutes on day 1 and pegfilgrastim subcutaneously on day 2. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients with objective response after 8 courses may receive additional therapy at the discretion of the physician.
Cohorts of 3-6 patients receive escalating doses of epirubicin and docetaxel until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
- Phase II:
Group 1 (21-day regimen) (closed to accrual as of 5/10/06): Patients receive treatment as in phase I with epirubicin and docetaxel at the recommended Phase II dose.
Group 2 (14-day regimen): Patients receive treatment as in phase I with epirubicin and docetaxel at the recommended Phase II dose.
Patients are followed at 1 month, every 3 months for 1 year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: Approximately 90 patients will be accrued for this study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Pegfilgrastim, docetaxel and epirubicin
|
Biological: pegfilgrastim
Dose escalation schedule A&B = 6mg fixed dose once per cycle on day 2
Drug: docetaxel
Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
Drug: epirubicin hydrochloride
Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
|
Outcome Measures
Primary Outcome Measures
- Toxic effects [7 years]
Findings were presented at ASCO 2010
- Response (phase II) [12 years]
Response was presented at ASCO 2010. Duration of response will be analyzed in 2015
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Histologically confirmed invasive adenocarcinoma of the breast, meeting any of the following criteria:
-
T4, NX, M0
-
Any T, N2-N3, M0
-
Inflammatory breast cancer (redness over at least one-third of the breast), M0
-
No evidence of metastatic disease by chest x-ray, abdominal ultrasound or CT scan and bone scan
-
Diagnosed within the past 8 weeks
-
Hormone receptor status:
-
Not specified
PATIENT CHARACTERISTICS:
Age
- 16 and over
Sex
- Female
Menopausal status
- Not specified
Performance status
- ECOG 0-2
Life expectancy
- Not specified
Hematopoietic
-
Absolute granulocyte count at least 2,000/mm^3
-
Platelet count at least 100,000/mm^3
-
Hemoglobin at least 10 g/dL
Hepatic
-
Bilirubin less than upper limit of normal (ULN)
-
Must meet criteria for 1 of the following:
-
ALT and AST no greater than 1.5 times ULN AND alkaline phosphatase no greater than 2.5 times ULN
-
ALT and AST normal AND alkaline phosphatase no greater than 5 times ULN
Renal
- Creatinine no greater than 1.5 times ULN
Cardiovascular
-
Resting LVEF normal by MUGA or echocardiogram
-
No congestive heart failure
-
No angina pectoris
-
No myocardial infarction within the past year
-
No uncontrolled hypertension
-
No uncontrolled arrhythmias
Other
-
Not pregnant or nursing
-
Negative pregnancy test
-
Fertile patients must use effective non-hormonal contraception
-
No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer or curatively treated carcinoma in situ of the cervix
-
No symptomatic peripheral neuropathy grade 2 or greater
-
No active infection
-
No history of significant neurological or psychiatric disorders, including dementia or seizures
-
No peptic ulcer
-
No unstable diabetes mellitus
-
No contraindication to dexamethasone
-
No known sensitivity to E. coli-derived or polyethylene glycol products
-
Willing to undergo core biopsies once prior to registration and core biopsies at 2 other timepoints while on study
-
Geographically accessible for treatment and follow-up
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No prior immunotherapy for breast cancer
Chemotherapy
- No prior chemotherapy for breast cancer
Endocrine therapy
-
No prior hormonal therapy for breast cancer
-
No concurrent corticosteroids except for premedication or hypersensitivity reaction
-
No concurrent oral contraception
Radiotherapy
- No prior radiotherapy for breast cancer
Surgery
- No prior surgery for breast cancer other than biopsy
Other
-
No prior systemic therapy for breast cancer
-
No other concurrent investigational drugs or anticancer treatment
-
No concurrent preventative IV antibiotics
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | CancerCare Manitoba | Winnipeg | Manitoba | Canada | R3E 0V9 |
2 | Atlantic Health Sciences Corporation | Saint John | New Brunswick | Canada | E2L 4L2 |
3 | Odette Cancer Centre | Toronto | Ontario | Canada | M4N 3M5 |
4 | Univ. Health Network-Princess Margaret Hospital | Toronto | Ontario | Canada | M5G 2M9 |
5 | CHA-Hopital Du St-Sacrement | Quebec City | Quebec | Canada | G1S 4L8 |
Sponsors and Collaborators
- NCIC Clinical Trials Group
Investigators
- Study Chair: Maureen E. Trudeau, BSc, MA, MD, FRCPC, Toronto Sunnybrook Regional Cancer Centre
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MA22
- CAN-NCIC-MA22
- CDR0000316237